SynthesisClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis.
Synthesis in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCurrent guidelines recommend that anticoagulation is reasonable and less robust to prevent stroke among AF patients with an intermediate risk of stroke, suggesting the need for more evidence in this population. Therefore, our current systematic review and meta-analysis aimed to evaluate the effectiveness and safety outcomes of oral anticoagulation (OAC) therapy in AF patients with a single additional stroke risk factor (CHA2DS2-VASc score = 1 in males and 2 in females).MethodsWe performed the literature searches to identify relevant articles by systematically researching the PubMed and Embase databases. In the pooled analysis by the random-effects model, the comparative treatment indicators to present outcomes of OAC therapy compared with no OAC were adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).ResultsA total of 6 studies were finally included. In the pooled analysis by the random-effects model, compared with no OAC therapy, OAC use was associated with increased risks of major bleeding (HR = 1.29, 95%CI: 1.06-1.57) and gastrointestinal bleeding (HR = 1.38, 95%CI: 1.04-1.82). There were no differences in stroke or systemic embolism (SSE) (HR = 0.84, 95%CI: 0.66-1.08), ischemic stroke (HR = 0.79, 95%CI: 0.27-2.33), and intracranial bleeding (HR = 1.17, 95%CI: 0.78-1.76) between the two studied groupsConclusionIn patients with AF patients at an intermediate risk of stroke, OAC use was not associated with reductions in thromboembolic events, but might increase the bleeding risks compared with no treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.